Related Experiment Video
Updated: Jan 5, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
[French ccAFU guidelines - Update 2018-2020: Prostate cancer]
F Rozet1, C Hennequin2, J-B Beauval3
1Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, institut mutualiste Montsouris, université René-Descartes, 42, boulevard Jourdan, 75674 Paris, France.
Updated French guidelines for prostate cancer (PCa) offer evidence-based recommendations for diagnosis, treatment, and follow-up. Key findings include active surveillance for low-risk PCa and new standards for metastatic disease management.
Area of Science:
- Urology
- Oncology
Context:
- Prostate cancer (PCa) diagnosis and treatment require updated clinical guidelines.
- The French national committee ccAFU aimed to provide evidence-based recommendations.
Purpose:
- To propose updated French guidelines for prostate cancer (PCa) management.
- To synthesize current evidence on PCa diagnosis, treatment, and follow-up.
Summary:
- A systematic review of literature from 2016-2018 informed the guidelines.
- Recommendations cover active surveillance for low-risk PCa, radical prostatectomy, and radiotherapy (≥76Gy).
- Management of intermediate and high-risk PCa involves radiotherapy with androgen deprivation therapy (ADT), while metastatic disease benefits from chemotherapy and novel hormonal agents like abiraterone acetate.
Impact:
- These guidelines aim to enhance the quality of urological care for prostate cancer patients in France.
- Implementation is expected to improve patient outcomes and standardize treatment protocols.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
Cancer Survival Analysis
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Standards of Care II

